Minoxidil oral 1 mg

Point de départ élevé : deux essais randomisés à risque de biais modéré, sans placebo. Dégradé de deux niveaux, pour imprécision (26 femmes par bras) et caractère indirect : comparaison au minoxidil topique dans l'un, à une dose plus faible dans l'autre.

Niveau abaissé pour : imprécision, caractère indirect.

La conclusion pourrait changer avec des essais de meilleure qualité.

Femmes de 18 à 65 ans atteintes d'alopécie androgénétique. Suivi de six mois. Le minoxidil oral fait plus souvent pousser des poils ailleurs que sur le crâne (voir la synthèse sur la pilosité).

• Densité capillaire totale
  164,6 → 184,7 cheveux par cm² Minoxidil oral 1 mg face à Minoxidil topique 5 %
  24 semaines · écart qui peut être dû au hasard · Ramos 2020
  Voir la citation

  Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01

  Citation complémentaire (valeur)

  Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09

  Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Densité capillaire totale 1 application par jour
  163,2 → 176,3 cheveux par cm² Minoxidil topique 5 % face à Minoxidil oral 1 mg
  24 semaines · écart qui peut être dû au hasard · Ramos 2020
  Voir la citation

  Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01

  Citation complémentaire (valeur)

  Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09

  Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Densité capillaire totale
  277,2 → 304 cheveux par cm² Minoxidil oral 1 mg face à Minoxidil oral 0,25 mg
  24 semaines · écart probablement réel · Nascimento 2022
  Voir la citation

  shaft count/cm2 (baseline, 292.0 6 63.1; 24 weeks, 299.8670.7;P¼.20;TableII),whilegroup2hada significant increase (baseline, 277.2 6 46.6; 24weeks,304.0639.0;P\.001;SupplementalFig 2). Between the 2 groups, a statistically significant differencewasfoundinthehairshaftcountovertime (P¼.008).

  Nascimento E Silva M, Ramos PM, Silva MR et al.. Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg.. J Am Acad Dermatol 2022, DOI 10.1016/j.jaad.2022.01.017. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Densité capillaire totale
  292 → 299,8 cheveux par cm² Minoxidil oral 0,25 mg face à Minoxidil oral 1 mg
  24 semaines · écart probablement réel · Nascimento 2022
  Voir la citation

  shaft count/cm2 (baseline, 292.0 6 63.1; 24 weeks, 299.8670.7;P¼.20;TableII),whilegroup2hada significant increase (baseline, 277.2 6 46.6; 24weeks,304.0639.0;P\.001;SupplementalFig 2). Between the 2 groups, a statistically significant differencewasfoundinthehairshaftcountovertime (P¼.008).

  Nascimento E Silva M, Ramos PM, Silva MR et al.. Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg.. J Am Acad Dermatol 2022, DOI 10.1016/j.jaad.2022.01.017. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Point de départ élevé : trois essais randomisés, petits (12 à 33 patients par bras), dont un à risque de biais élevé. Dégradé de deux niveaux, pour imprécision (quelques cas par bras) et pour risque de biais. Les trois essais vont dans le même sens, et l'écart atteint la significativité dans le plus solide. Aucun ne compare le minoxidil oral au placebo.

Niveau abaissé pour : imprécision, risque de biais.

La conclusion pourrait changer avec des essais de meilleure qualité.

Surtout des femmes de 18 à 65 ans ; un essai inclut des hommes. Suivi de six mois.

• Incidence d'une pilosité accrue
  27 % (7 sur 26) Minoxidil oral 1 mg face à Minoxidil topique 5 %
  24 semaines · écart probablement réel · Ramos 2020
  Voir la citation

  Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27)

  Citation complémentaire (valeur)

  Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02

  Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Incidence d'une pilosité accrue 1 application par jour
  4 % (1 sur 26) Minoxidil topique 5 % face à Minoxidil oral 1 mg
  24 semaines · écart probablement réel · Ramos 2020
  Voir la citation

  Table 2. Main results and adverse effects of the comparative 9 effectiveness of oral minoxidil 1mg versus topical 5% minoxidil solution for twenty-four weeks in the treatment of FPHL (n=52). Oral Minoxidil 1mg T0 T24 p-value* Hair density# – per cm2 Total hair 164.6 (48.1) 184.7 (57.1) <0.01 Terminal hair 106.5 (34.2) 112.6 (36.4) 0.03 Global photograph## Slightly impaired - 1 (4) - No change - 7 (27) - Slightly improved - 16 (62) - Greatly improved - 2 (8) Hair shedding score### 5 (3-5) 3 (2-3) <0.01 WAA-QoL### 68 (51-80) 15 (6-36) <0.01 Adverse effects Edema of the limbs## - 1 (4) Hyperthrichosis## - 7 (27)

  Citation complémentaire (valeur)

  Topical Minoxidil 5% p-value (time*group) T0 T24 p-value* 163.2 (46.0) 176.3 (61.5) <0.01 0.09 113.3 (41.1) 116.8 (44.9) 0.09 0.17 0.16 - 2 (8) - - 12 (46) - - 11 (42) - 1 (4) 4 (3-5) 4 (3-5) 0.20 <0.01 60 (28-77) 25 (11-41) <0.01 0.09 - 0 (-) 0.99 - 1 (4) 0.02

  Ramos PM, Sinclair RD, Kasprzak M et al.. Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial.. J Am Acad Dermatol 2020, DOI 10.1016/j.jaad.2019.08.060. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Incidence d'une pilosité accrue
  2 sur 12 Minoxidil oral 1 mg face à Minoxidil oral 0,25 mg
  24 semaines · Nascimento 2022
  Voir la citation

  SupplementalTableII).At24-weekfollowup,mild facial hypertrichosis was observed in 2 patients

  Nascimento E Silva M, Ramos PM, Silva MR et al.. Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg.. J Am Acad Dermatol 2022, DOI 10.1016/j.jaad.2022.01.017. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

• Incidence d'une pilosité accrue
  2 patients Minoxidil oral 1 mg face à Minoxidil topique 5 %
  26 semaines · Asilian 2023
  Voir la citation

  Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

  Citation complémentaire (methode)

  In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

  Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.

• Incidence d'une pilosité accrue
  1 patient Minoxidil topique 5 % face à Minoxidil oral 1 mg
  26 semaines · Asilian 2023
  Voir la citation

  Overall, no serious adverse effects were reported during the OA 6-month trial. One patient in the oral minoxidil group reported articles orthostatic hypotension, which was readily managed by raising are governed her daily salt consumption and the patient continued the study. Minoxidil-induced telogen effluvium occurred in three and four pa- by tients in oral and topical minoxidil groups respectively. This led to the applicable drop out of all patients in the topical group. Two patients in the oral group experienced hypertrichosis on their face and extremities, one Creative of whom quit the study. Similarly, in the topical group, one patient left the study due to facial hypertrichosis (Figure 1). Commons

  Citation complémentaire (methode)

  In order to ensure accurate measurements, three specific loca- tions on the scalp were identified and marked with tattoos (Jet Black Micropigment, BioTouch Company, USA). These locations were located at distances of 12, 16, and 24 cm from the glabella, and were referred to as the frontal, mid-frontal, and vertex points, respectively. A single drop of ink was placed on the targeted area and an insulin needle was used to tattoo the ink onto the skin.19 Macrophotographs of the tattooed areas were taken by a dermo- scopic device (FotoFinder System Gmbh) connected to a cell phone and a camera (Canon EOS M100 camera). A technician who was experienced in the field of trichology and blinded to the treatment manually counted the number of hairs within a 1 cm2 area surround- ing each tattoo point. The thickness of five randomly selected hairs in close proximity to the tattooed area was measured using 3D Slicer 5.2.2 software and then averaged.

  Asilian A, Farmani A, Saber M. Clinical efficacy and safety of low-dose oral minoxidil versus topical solution in the improvement of androgenetic alopecia: a randomized controlled trial. Journal of Cosmetic Dermatology 2023, DOI 10.1111/jocd.16086. Citation sous licence CC-BY.